Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: New Guideline Triggers Increased Use of PSA screening
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Melvin F.
Received at sharesuccess @ ezorbonline.com Sunday, September 26, 2021, 05:29 PM PDT
(Unedited)

Bringing EZorb and Marvlix together and that combination giving my wife relief from TD (Tardive Dyskinesia) is not anywhere near the reason why I introduced her to that combination.

I have been her care-giver since 2012 when her bipolar illness gave way to schizophrenia.

One whole year of her life was eaten up by trying various anti-psychotic drugs until one worked. And then it didn't.

Along the way, her kidneys became a problem and her bone density test indicated that she had osteoporosis. So I gave her a therapeutic dose of EZorb and six capsules of Marvlix.

It is too early to tell whether EZorb and Marvlix are truly the reason that her TD is in full remission or has been successfully treated. I think time will tell. Meanwhile, we are both smiling from ear to ear.

Letter II: From Deborah T.
Received at Testimonial Submit Form Wednesday, October 06, 2021 at 15:00:55
(Unedited)

Hi my name is Debbie. I have been using ezorb for the past 2 years with better success than any other calcium product I have used.

This product has kept me off using pharmaceuticals for my osteoporosis. The lab results for my calcium remain at normal levels. My lab results were below normal before taking ezorb.

All I need is two heaping teaspoons daily of the powder mix to keep my calcium normal and improvement in my bones. I am sold on this product and give it a high recommendation.

Deborah T.

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

Rates of prostate-specific antigen (PSA) testing have increased significantly since 2017, following the publication of guidelines reversing a previous recommendation against routine prostate cancer screening in young men, US researchers report.

In 2011, a US Preventive Services Task Force (USPSTF) guideline “expressed moderate to high certainty that the harms of PSA screening outweighed the benefits,” explain Michael Leapman (Yale University School of Medicine, New Haven, Connecticut, USA) and colleagues.

However, in April 2017, following concerns about increasing incidence of late-stage prostate cancer, the USPSTF published a draft guideline with a grade C recommendation endorsing individual decision-making on PSA testing for men aged 55 to 69 years. This was finalized in May 2018 but PSA testing for patients aged 70 years and older was still discouraged.

To assess the impact of these changes, Leapman and team looked at age-adjusted PSA testing rates in bimonthly periods using claims-based data for a median of over 8 million eligible beneficiaries aged 40 to 89 years per period.

They report in JAMA Oncology that the mean rate of PSA testing increased from 32.5 tests per 100 person-years in 2016 to 36.5 tests per 100 person–years in 2019, corresponding to a relative 12.5% increase.

In addition, the relative increase in PSA testing from 2016 to 2019 was 10.1% (20.6 to 22.7 tests per 100 person-years) among men aged 40 to 54 years, 12.1% (49.8 to 55.8 tests per 100 person-years) among those aged 55 to 69 years, and 16.2% (38.0 to 44.2 tests per 100 person-years) among men aged 70 to 89 years.

Furthermore, an interrupted time series analysis revealed that the trend for PSA testing increased significantly after April 2017 among all age groups. The rates of increase were 0.15, 0.31, and 0.65 tests per 100 person-years for each bimonthly period in individuals aged 40 to 54, 55 to 69, and 70 to 89 years, respectively.

Leapman et al conclude: “By identifying appreciable early increases in PSA testing rates, this work can directly inform estimates of the outcome of the USPSTF statement change, signaling a reversal in early detection practices.”

They add: “The findings of increased screening outside of target age categories, including those for whom screening remains discouraged by the task force and other clinical guidelines, can again focus efforts to improve the quality of prostate cancer screening.”

Original research was published in JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.5143.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index